SGMT News - Candlesense

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional meta...

Investor

15 days ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China

How does this clinical success impact the overall risk profile of Sagimet's pipeline and its long‑term growth prospects? What is the projected market size for moderate to severe acne in China and globally, and how much market share can Sagimet realistically capture? Are there any contingent milestones or royalty structures tied to the Ascletis partnership that could impact future earnings?

Earnings

28 days ago